Why Suboxone Might Not Be Working: Read This First

Why bupe sometimes doesn't cover you: serotonergic and adrenergic symptoms, the dose-ceiling question, long-acting compounds.

If you’re freaking out because bupe isn’t doing what you thought it would: you’re not broken, your medication isn’t broken, and you’re not failing. There are well-understood reasons it can feel inadequate, especially coming off 7-OH and related compounds. Standard Suboxone protocols were built around heroin, oxy, and prescription opioids. What we’re recovering from is different in several ways, and the medication needs to be used a little differently to fully cover what’s happening.

This community leans toward short-term tapers, so most of what’s below is about how to make bupe work well enough to get you through to the other side, not about long-term maintenance.

The big one: bupe doesn’t touch the serotonergic and adrenergic side of withdrawal

This is the part most people aren’t told, and it’s the single biggest reason Suboxone feels incomplete for our population.

7-OH and the related synthetics are not pure opioids. Kratom’s minor alkaloids (paynantheine, speciogynine, corynantheidine, and others) bind serotonin and adrenergic receptors directly. The peer-reviewed literature shows paynantheine and speciogynine bind 5-HT₁ₐ at low-nanomolar affinity (Ki ≈ 32 and 39 nM), with their liver metabolites acting as full 5-HT₁ₐ agonists (León et al., J Med Chem 2021). Corynantheidine binds α-1D adrenergic receptors selectively (Ki ≈ 42 nM) and mitragynine itself behaves as a low-efficacy α-2A agonist (Obeng et al., J Med Chem 2020; Obeng et al., Eur J Pharmacol 2024).

That’s not how an SSRI or SNRI works, those drugs block the serotonin and norepinephrine transporters, and no peer-reviewed binding study has ever shown a kratom alkaloid doing that (Kamble et al., Front Pharmacol 2021). Kratom reaches the same receptor families by binding the receptors themselves. The dependence you’ve built isn’t just opioid-receptor adaptation, it’s to a compound that’s been stimulating mu-opioid receptors plus serotonin and adrenergic receptors directly, all at once.

When you stop, you don’t just get opioid withdrawal. You get opioid withdrawal plus adaptation of serotonergic and adrenergic receptor systems, all at the same time, a profile a 2023 expert forum attributes to kratom’s “non-opioid alpha-adrenergic, serotonergic, and other pharmacological effects” (Henningfield et al., Drug Alcohol Depend Rep 2023). That’s a different physiological event than what classical opioid recovery resources describe.

Suboxone is purely opioid-receptor medication. It does an excellent job covering the opioid side. It does nothing for the serotonergic or adrenergic side. So those symptoms don’t go away just because you started bupe. The picture often resembles SSRI/SNRI discontinuation (same receptor families, similar-feeling symptoms) even though the mechanism is different. Specifically:

  • Wired anxiety. Not the calm-but-uneasy kind, the can’t-sit-still, jumping-out-of-skin kind.
  • Insomnia that doesn’t respond to feeling tired. Your body is exhausted, your brain is wide awake.
  • Brain zaps. That electric, jolting sensation in your head, sometimes with movement. The same symptom people describe coming off an SSRI or SNRI.
  • Restless legs and arms, especially at night.
  • Crying jags or emotional lability. Sudden tears or irritability with no clear trigger.
  • Sensory hypersensitivity. Lights too bright, sounds too loud, skin too sensitive.
  • Sweating, especially at night, even when bupe is otherwise covering you.
  • A specific “off” feeling that you can tell is different from opioid withdrawal but you can’t quite name.

If any of this sounds like what you’re experiencing on bupe, bupe is doing its job and there’s a separate piece that needs separate help. The fix is not more bupe. The fix is adjuncts.

Adjuncts for the serotonergic and adrenergic piece

Provider attitudes vary on which adjuncts they’ll add; see the telehealth providers comparison if you need a prescriber who works with kratom/7-OH dependence.

  • Clonidine. Alpha-2 agonist. Takes the edge off the noradrenergic symptoms (sweating, anxiety, fast heart rate, restlessness). Most prescribers familiar with MAT will prescribe this on request.
  • Hydroxyzine. Non-addictive antihistamine that helps with anxiety and sleep without controlled-substance risk. Easy to get prescribed. Caveat: hydroxyzine is a first-generation antihistamine (H1 antagonist), and antihistamines have been associated with worsening restless legs syndrome and may exacerbate other withdrawal symptoms in some people. If you’re already struggling with RLS, twitchy legs, or jumpy/agitated symptoms, hydroxyzine may make these worse rather than better. Worth trying carefully, but if you notice your legs getting worse after starting it, that’s a known mechanism and a reason to switch to a different adjunct.
  • Gabapentin. Anxiety, restless legs, sleep, brain zaps. effective.
  • Trazodone. Sleep specifically, especially the broken/restless sleep that hits hard during this phase.
  • Baclofen. Muscle relaxant; helps with the body tension and aches that are partly opioid and partly noradrenergic.
  • Magnesium glycinate. OTC. helps with the restless-legs, muscle-tension, anxiety cluster.
  • L-theanine. OTC. Takes the edge off without sedation.

See Vitamins & Supplements for the full picture on supplement support.

Dose: you might need more

This is the second-biggest thing people don’t get told. The “right” dose of bupe varies a lot between people, and landing at too low a dose is one of the most common reasons bupe feels inadequate.

This community uses a low-and-slow induction (start at 2 mg, titrate up by 1 mg as needed) precisely because we don’t want people parked at a higher dose than they need. But the flip side is also true: if you’re parked too low, the bupe isn’t covering you, and that’s a fixable problem.

If you’re at 2 mg and you’re still feeling withdrawal symptoms throughout the day, your dose is probably too low. If you’re at 4 mg and feeling waves of return-of-symptoms before your next dose, your dose is probably too low. Most people coming off 7-OH land somewhere in the 4 to 8 mg range when fully covered. Some need less, some need more.

On the dose ceiling: the conventional wisdom held that buprenorphine has a flat ceiling at 24 to 32 mg/day, meaning higher doses don’t add benefit. More recent research has challenged this, suggesting the ceiling effect is more individual than the older guidance assumed and some patients do get meaningful benefit at higher doses. This community doesn’t generally encourage going above 8 mg/day because higher doses make tapering harder and longer, and most 7-OH users don’t need it. But if your prescriber suggests a higher dose because you’re not stabilizing, the newer research supports that being a reasonable approach.

The practical takeaway: if you’re struggling on bupe, before assuming the medication isn’t working, check whether you’re at a dose that covers you. Track when symptoms return relative to dosing. If they’re returning hours before your next dose, talk to your prescriber about either a higher dose or splitting your daily dose into two smaller doses (morning and evening) to keep blood levels more stable.

If you’ve been on long-acting synthetics or stacked compounds

Most people in this community are coming off 7-OH, but if you’ve also been on MGM-15, or pseudo, the picture changes meaningfully:

MGM-15 is a dual mu/delta receptor agonist (Matsumoto 2014 reports MOR Kᵢ 6.4 nM, DOR Kᵢ 16 nM). Buprenorphine is essentially mu-only and is a delta antagonist. The delta contribution to mood, analgesia, and overall opioid tone gets removed entirely when you switch off MGM-15. This shows up as restlessness, anhedonia, low mood, and a persistent low-grade “off” feeling that lasts longer than 7-OH users typically experience. That’s pharmacology, not your imagination. See MGM-15 for the full breakdown, and Depression and Anhedonia for the broader treatment picture for these symptoms.

Pseudo (mitragynine pseudoindoxyl) binds the mu receptor tighter than buprenorphine itself does (Varadi 2016 reports MP Kᵢ ≈ 0.8 nM vs bupe ~1.5 nM). Even when bupe is on board, displacement and stabilization can be incomplete in a way that doesn’t happen with 7-OH.

Products marketed as MIT-A or DHM contain MGM-15 mixed with concentrated mitragynine. Treat induction the same as for MGM-15: longer washout, potentially higher stabilization doses, and expect the first 2–3 days to be the hardest because bupe doesn’t fully cover MGM-15’s delta-receptor contribution.

If any of these were in the mix, be honest with your prescriber about what you’ve used. Most providers haven’t heard of these compounds, and if they’re running the standard kratom playbook on someone who’s been on a long-acting full mu/delta agonist, of course bupe isn’t going to feel right.

There’s also a partial agonist ceiling effect that matters here: bupe activates mu receptors less than full agonists do. Coming off MGM-15 or pseudo, you’re stepping receptor activation down rather than replacing it 1:1. For 7-OH this gap is usually manageable; for the heavier synthetics it’s significant.

If standard induction itself failed: precipitated withdrawal, couldn’t wait long enough, or symptoms wouldn’t stabilize regardless of dose, the Bernese method (micro-induction) is the alternative induction pathway for the long-acting compounds. Different mechanics: you keep your opioid going and ramp bup in over 5–10 days, instead of waiting in withdrawal and dosing larger at the bottom of the wait. Most clinical evidence is in fentanyl and methadone populations; the kratom-derivative experience is community-extrapolated rather than published. Bring it up with a prescriber if standard induction isn’t a fit for your situation.

Steps to take right now if Suboxone isn’t working

  1. Check the serotonergic/adrenergic piece first. If you have any of the symptoms in the list above, that’s where the problem is. Get clonidine, gabapentin, or trazodone added (see Helper Medications for the full menu, including the meds with RLS caveats).
  2. Check your dose. Are you covered, or parked too low? If symptoms return before your next dose, your dose is too low or you need to split it.
  3. Be honest about what you were on. If MGM-15, or pseudo were in the mix, the playbook changes.
  4. Don’t bail in the first 1-2 days. This is when most people quit, because it’s when bupe feels least like what their body was used to and the non-opioid symptoms are at their worst. Your dose may not be dialed in yet, your adjuncts may not be in your system yet. Push through to day 2 or 3 with the right dose and adjuncts in place.
  5. Don’t redose your old compound to take the edge off. That’s how this restarts.
  6. Talk to the community. People in our Discord and subreddit have lived through what you’re going through with these specific compounds.

When to seek emergency help

  • Severe symptoms that won’t resolve and feel unmanageable
  • Any thoughts of self-harm or suicide. Call or text 911.
  • Inability to keep down fluids for more than 24 hours
  • Severe chest pain or irregular heartbeat
  • Mental health crisis

None of those is giving up. They’re tools.

A note on patience

The standard recovery resources tell you bupe will make you feel “back to normal” pretty quickly. For our population, that’s not always true on the standard timeline. The first few days are the hardest, and day 1 to 2 is when most people in this community quit. That’s exactly the window where bupe hasn’t fully kicked in, your dose probably isn’t optimized yet, and the serotonergic/adrenergic symptoms haven’t responded to adjuncts that need a day or two to take effect. Push through. Adjuncts help. The right dose helps. By day 4 or 5 most people are in noticeably better shape than day 1 or 2.

If you’re approaching the end of your taper and still feel terrible, talk to your prescriber, and post in the Discord or subreddit for community input. There may be something specific to your situation worth troubleshooting.

Sources

Last updated: View source on GitHub